# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test,...
Baird analyst Catherine Ramsey maintains Castle Biosciences (NASDAQ:CSTL) with a Outperform and raises the price target from...
Castle Biosciences (NASDAQ:CSTL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(...
Castle's second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical u...